ALK invested DKK 1bn in US breakthrough: "It didn't pan out the way we'd hoped"

Large investments in the establishment of a US organization have still not produced the desired outcome for allergy firm ALK. "I had thought we'd be 25 percent larger in the US than we are today," CEO Carsten Hellmann tells MedWatch.

ALK President & CEO Carsten Hellmann. | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix

When ALK President & CEO Carsten Hellmann in late 2017 raised money for an extensive three-year growth plan, one of the firm's major priorities was to turn the US market into the company's largest.

To this purpose, Denmark-based allergy firm ALK invested a total of DKK 1bn (USD 162.8m) in the establishment of a US sales organization, the execution of clinical studies on children and asthma, and persuasive efforts to get allergologists to swap out injection-based vaccines with ALK's tablet porfolio.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs